Heart Failure IDentification in a High Risk Cardiovascular OutpatiEnt Population (HIDE)

NACompletedINTERVENTIONAL
Enrollment

317

Participants

Timeline

Start Date

January 31, 2020

Primary Completion Date

June 7, 2021

Study Completion Date

June 11, 2021

Conditions
Heart Failure
Interventions
DIAGNOSTIC_TEST

NYHA assessment

The New York Heart Association (NYHA) functional classification of HF

PROCEDURE

Serum NT-proBNP concentration

Subjects with NYHA score ≥ II will undergo a rapid, on site serum NT-proBNP test on the same day of the visit. Roche CARDIAC proBNP+ test, using the Cobas h 232 device, is a quantitative immunological test for the determination of NT-proBNP in heparinized venous blood.

DIAGNOSTIC_TEST

Transthoracic Ecocardiogram

Subjects with a serum NT-proBNP result of ≥ 125 pg/mL at Visit 1 will be referred to a study cardiologist for a transthoracic echocardiogram to assess LVEF and relevant structural heart disease

Trial Locations (5)

1101

Novartis Investigative Site, San Salvador

10203

Novartis Investigative Site, Santo Domingo

Unknown

Novartis Investigative Site, Santo Domingo

01009

Novartis Investigative Site, Guatemala City

01010

Novartis Investigative Site, Guatemala City

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY